• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Takeda consolidates U.S. vaccine sites in Massachusetts

Takeda consolidates U.S. vaccine sites in Massachusetts

June 4, 2015
CenterWatch Staff

Takeda Pharmaceutical will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza.

The Boston/Cambridge, Mass. area, and Zurich, Switzerland, will serve as VBU’s global hubs for the vaccine business outside of Japan. VBU will maintain regional hubs in Singapore and in Brazil and will operate manufacturing sites in Hikari, Japan; Durham, N.C., and Singen, Germany.

In the U.S., all vaccine activities, with the exception of manufacturing, will move to the new global hub in the Boston/Cambridge area. This co-location will significantly enhance communication and collaboration across VBU’s divisions, and will allow VBU to leverage Takeda’s R&D presence in Cambridge. It also will provide access to the area’s biotech/pharmaceutical ecosystem and talent base.

Takeda will close its vaccine site in Bozeman, Mont., which it obtained through the acquisition of LigoCyte Pharmaceuticals in 2012, as well as the Madison, Wis., and Fort Collins, Colo., sites, which came to Takeda through the acquisition of Inviragen in 2013. In addition, vaccine activities in Deerfield, Ill., which currently is the global headquarters for VBU, will shift to the Boston/Cambridge area. This transition will occur in phases over the next two years, with the completion of U.S. consolidation by mid-2017.

“Takeda remains fully committed to the development of innovative vaccines that improve the lives of people around the world, including our norovirus, dengue and seasonal influenza candidate vaccines,” said Rajeev Venkayya, M.D., president, Takeda’s VBU. “Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development. This consolidation will help us to achieve the efficiency and operational excellence needed to execute the phase III clinical programs and set the stage for global commercialization of these vaccines.”

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing